Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Rajesh Agarwal to Antioxidants

This is a "connection" page, showing publications Rajesh Agarwal has written about Antioxidants.

 
Connection Strength
 
 
 
4.846
 
  1. Tilley C, Deep G, Agarwal C, Wempe MF, Biedermann D, Valentov? K, Kren V, Agarwal R. Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation. Mol Carcinog. 2016 Jan; 55(1):3-14.
    View in: PubMed
    Score: 0.366
  2. Deep G, Agarwal R. Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Targets. 2013 Jun; 13(5):486-99.
    View in: PubMed
    Score: 0.330
  3. Ting H, Deep G, Agarwal R. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J. 2013 Jul; 15(3):707-16.
    View in: PubMed
    Score: 0.327
  4. Mateen S, Raina K, Agarwal C, Chan D, Agarwal R. Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J Pharmacol Exp Ther. 2013 May; 345(2):206-14.
    View in: PubMed
    Score: 0.324
  5. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010 Sep; 29(3):447-63.
    View in: PubMed
    Score: 0.272
  6. Mateen S, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol Carcinog. 2010 Mar; 49(3):247-58.
    View in: PubMed
    Score: 0.263
  7. Singh RP, Agarwal R. Cosmeceuticals and silibinin. Clin Dermatol. 2009 Sep-Oct; 27(5):479-84.
    View in: PubMed
    Score: 0.254
  8. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2008 Aug 15; 68(16):6822-30.
    View in: PubMed
    Score: 0.236
  9. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther. 2007 Oct; 6(10):2696-707.
    View in: PubMed
    Score: 0.223
  10. Singh RP, Dhanalakshmi S, Mohan S, Agarwal C, Agarwal R. Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells. Mol Cancer Ther. 2006 May; 5(5):1145-53.
    View in: PubMed
    Score: 0.202
  11. Kandhari K, Kant R, Mishra N, Agarwal C, Agarwal R. Phenylarsine oxide induced corneal injury involves oxidative stress mediated unfolded protein response and ferroptotic cell death: Amelioration by NAC. Free Radic Biol Med. 2023 11 20; 209(Pt 2):265-281.
    View in: PubMed
    Score: 0.170
  12. Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal. 2002 Aug; 4(4):655-63.
    View in: PubMed
    Score: 0.156
  13. Rigby CM, Roy S, Deep G, Guillermo-Lagae R, Jain AK, Dhar D, Orlicky DJ, Agarwal C, Agarwal R. Role of p53 in silibinin-mediated inhibition of ultraviolet B radiation-induced DNA damage, inflammation and skin carcinogenesis. Carcinogenesis. 2017 01; 38(1):40-50.
    View in: PubMed
    Score: 0.104
  14. Guillermo-Lagae R, Deep G, Ting H, Agarwal C, Agarwal R. Silibinin enhances the repair of ultraviolet B-induced DNA damage by activating p53-dependent nucleotide excision repair mechanism in human dermal fibroblasts. Oncotarget. 2015 Nov 24; 6(37):39594-606.
    View in: PubMed
    Score: 0.098
  15. Tilley C, Deep G, Agarwal R. Chemopreventive opportunities to control basal cell carcinoma: Current perspectives. Mol Carcinog. 2015 Sep; 54(9):688-97.
    View in: PubMed
    Score: 0.095
  16. Deep G, Kumar R, Jain AK, Agarwal C, Agarwal R. Silibinin inhibits fibronectin induced motility, invasiveness and survival in human prostate carcinoma PC3 cells via targeting integrin signaling. Mutat Res. 2014 Oct; 768:35-46.
    View in: PubMed
    Score: 0.090
  17. Kumar S, Raina K, Agarwal C, Agarwal R. Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by modulating interleukin 4/6-mediated survival signals. Oncotarget. 2014 Jul 15; 5(13):4972-89.
    View in: PubMed
    Score: 0.089
  18. Tewari-Singh N, Inturi S, Jain AK, Agarwal C, Orlicky DJ, White CW, Agarwal R, Day BJ. Catalytic antioxidant AEOL 10150 treatment ameliorates sulfur mustard analog 2-chloroethyl ethyl sulfide-associated cutaneous toxic effects. Free Radic Biol Med. 2014 Jul; 72:285-95.
    View in: PubMed
    Score: 0.088
  19. Ting HJ, Deep G, Jain AK, Cimic A, Sirintrapun J, Romero LM, Cramer SD, Agarwal C, Agarwal R. Silibinin prevents prostate cancer cell-mediated differentiation of na?ve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF ?2. Mol Carcinog. 2015 Sep; 54(9):730-41.
    View in: PubMed
    Score: 0.087
  20. Tewari-Singh N, Jain AK, Inturi S, Ammar DA, Agarwal C, Tyagi P, Kompella UB, Enzenauer RW, Petrash JM, Agarwal R. Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries. Toxicol Appl Pharmacol. 2012 Oct 01; 264(1):23-31.
    View in: PubMed
    Score: 0.078
  21. Narayanapillai S, Agarwal C, Tilley C, Agarwal R. Silibinin is a potent sensitizer of UVA radiation-induced oxidative stress and apoptosis in human keratinocyte HaCaT cells. Photochem Photobiol. 2012 Sep-Oct; 88(5):1135-40.
    View in: PubMed
    Score: 0.075
  22. Deep G, Gangar SC, Agarwal C, Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila). 2011 Aug; 4(8):1222-32.
    View in: PubMed
    Score: 0.071
  23. Ravichandran K, Velmurugan B, Gu M, Singh RP, Agarwal R. Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Clin Cancer Res. 2010 Sep 15; 16(18):4595-606.
    View in: PubMed
    Score: 0.068
  24. Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia. 2010 May; 12(5):415-24.
    View in: PubMed
    Score: 0.067
  25. Rajamanickam S, Velmurugan B, Kaur M, Singh RP, Agarwal R. Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res. 2010 Mar 15; 70(6):2368-78.
    View in: PubMed
    Score: 0.066
  26. Rajamanickam S, Kaur M, Velmurugan B, Singh RP, Agarwal R. Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway. Pharm Res. 2009 Dec; 26(12):2558-67.
    View in: PubMed
    Score: 0.064
  27. Singh RP, Raina K, Deep G, Chan D, Agarwal R. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res. 2009 Jan 15; 15(2):613-21.
    View in: PubMed
    Score: 0.061
  28. Zhou L, Zhang Y, Gapter LA, Ling H, Agarwal R, Ng KY. Cytotoxic and anti-oxidant activities of lanostane-type triterpenes isolated from Poria cocos. Chem Pharm Bull (Tokyo). 2008 Oct; 56(10):1459-62.
    View in: PubMed
    Score: 0.060
  29. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int J Cancer. 2008 Jul 01; 123(1):41-50.
    View in: PubMed
    Score: 0.059
  30. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008 Oct 08; 269(2):352-62.
    View in: PubMed
    Score: 0.058
  31. Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 2008 Mar 15; 68(6):2043-50.
    View in: PubMed
    Score: 0.057
  32. Anwar A, Gu M, Brady S, Qamar L, Behbakht K, Shellman YG, Agarwal R, Norris DA, Horwitz LD, Fujita M. Photoprotective effects of bucillamine against UV-induced damage in an SKH-1 hairless mouse model. Photochem Photobiol. 2008 Mar-Apr; 84(2):477-83.
    View in: PubMed
    Score: 0.057
  33. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glod? LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2007 Nov 15; 67(22):11083-91.
    View in: PubMed
    Score: 0.056
  34. Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther. 2007 Jun; 6(2):130-45.
    View in: PubMed
    Score: 0.054
  35. Gu M, Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res. 2007 Apr 01; 67(7):3483-91.
    View in: PubMed
    Score: 0.054
  36. Kaur M, Agarwal R. Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicol Appl Pharmacol. 2007 Nov 01; 224(3):350-9.
    View in: PubMed
    Score: 0.052
  37. Flaig TW, Glod? M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010 Jun 01; 70(8):848-55.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)